You are here: home
Logo SFB-F44

SFB-F44 - Cell signaling in chronic CNS disorders

Welcome to SFB-F44

Chronic diseases of the central nervous system (CNS), such as fear/anxiety disorders and neurodegenerative diseases occur with high and increasing prevalence. Since molecular disease mechanisms are not fully understood, current drug therapies are often unsatisfactory. The development of novel and improved therapeutic strategies requires the identification of innovative targets for therapeutic intervention. The major goal of this SFB is to comprehensively study two signaling pathways that bear such potential: L-type calcium channels (LTCCs) and epigenetic modulators, in particular histone deacetylases (HDACs). Both pathways appear to participate in the etiology of several neurological disorders. Moreover, recent preliminary findings from our consortium suggest that they can be (patho-) physiologically linked.

We bundle our strong local expertise to study calcium mediated, epigenetic and non-coding RNA (ncRNA) - mediated regulatory mechanisms to disclose the role of these pathways for the pathophysiology of Parkinsonian disorders (Parkinson's disease, Multiple System Atrophy), Alzheimer's disease and abnormal fear and anxiety.


May 7th, 2019 
Wissen aktuell: Wissensdurst... more

April 23rd, 2019 
Nervenzellen völlig falsch verbunden... more  


September 24th-25th, 2019
Final Meeting SFB-f44, CCB, Innsbruck... more

September 25th-27th, 2019
ANA/APHAR Meeting 2019, CCB, Innsbruck ... more


April 16th, 2019
Addi Nii, Yale School of Medicine, Psychiatry ... more

May 21st, 2019
Ronald Melki, MIRCen, CEA & CNRS, Fontenay-...  more

» view more & news arcive » view more & event archive » view more & seminars archive

Member labs 2nd funding period:

Member labs 1st funding period:

  • L. Aigner, S. Couillard-Despres Molekulare Regenerative Medizin, Paracelcus Medizinische Privatuniversität
  • B. Flucher, G. Obermair - Physiologie, Medizinische Universität Innsbruck
  • C. Humpel, J. Marksteiner - Universitätsklinik für Allgemeine und Sozialpsychiatrie, Medizinische Universität Innsbruck
  • A. Hüttenhofer - Genomik und RNomik, Medizinische Universität Innsbruck
  • B. Liss - Angewandte Physiologie, Universität Ulm
  • A. Lusser - Molekularbiologie, Medizinische Universität Innsbruck
  • N. Singewald - Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Innsbruck
  • J. Striessnig, A. Koschak - Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Innsbruck und Zentrum für Physiologie und Pharmakologie, Medizinische Universität Wien
  • G. Wenning, N. Stefanova - Universitätsklinik für Neurologie, Medizinische Universität Innsbruck